{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:42:43Z","timestamp":1790772163269,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Plasma exchange and intravenous immunoglobulin are effective in treating Guillain\u2013Barr\u00e9 syndrome (GBS) probably because the former removes IgG autoantibodies and complement and the latter inhibits complement activation subsequent to the autoantibody binding to peripheral nerve antigens. IgG degrading enzyme of <jats:italic>Streptococcus pyogenes<\/jats:italic> (IdeS) can cleave the pathogenic autoantibodies into F(ab\u2019)<jats:sub>2<\/jats:sub> and Fc. The purpose of this study is to show whether IdeS has novel therapeutic potential for GBS. Sera with anti-ganglioside IgG antibodies from 15 patients with GBS or Miller Fisher syndrome were used. We tested whether IdeS cleaved the anti-ganglioside IgG antibodies and inhibited deposition of activated complement component on ELISA plates. IdeS efficiently cleaved IgG and blocked complement activation mediated by anti-GM1, anti-GD1a and anti-GQ1b IgG antibodies. IdeS has therapeutic potential for GBS and related conditions.<\/jats:p>","DOI":"10.1038\/srep10809","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T09:46:09Z","timestamp":1437471969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Streptococcal IdeS: therapeutic potential for Guillain\u2013Barr\u00e9 syndrome"],"prefix":"10.1038","volume":"5","author":[{"given":"Ryo","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,21]]},"reference":[{"key":"BFsrep10809_CR1","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","volume":"366","author":"N Yuki","year":"2012","unstructured":"Yuki, N. & Hartung, HP. Guillain\u2013Barr\u00e9 syndrome. N Engl J Med. 366: 2294\u22122304 (2012).","journal-title":"N Engl J Med."},{"key":"BFsrep10809_CR2","doi-asserted-by":"publisher","first-page":"11404","DOI":"10.1073\/pnas.0402391101","volume":"101","author":"N Yuki","year":"2004","unstructured":"Yuki, N. et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain\u2212Barr\u00e9 syndrome. Proc Natl Acad Sci USA. 101: 11404\u221211409 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep10809_CR3","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","volume":"27","author":"K Susuki","year":"2007","unstructured":"Susuki, K. et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci. 27: 3956\u22123967 (2007).","journal-title":"J Neurosci."},{"key":"BFsrep10809_CR4","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/brain\/awq119","volume":"133","author":"R McGonigal","year":"2010","unstructured":"McGonigal, R. et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain. 133: 1944\u22121960 (2010).","journal-title":"Brain"},{"key":"BFsrep10809_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.410390512","volume":"39","author":"CE Hafer-Macko","year":"1996","unstructured":"Hafer-Macko, CE. et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 39: 625\u2212635 (1996).","journal-title":"Ann Neurol."},{"key":"BFsrep10809_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/brain\/awh127","volume":"127","author":"G Zhang","year":"2004","unstructured":"Zhang, G. et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain. 127: 1085\u22121100 (2004).","journal-title":"Brain"},{"key":"BFsrep10809_CR7","doi-asserted-by":"publisher","first-page":"e107772","DOI":"10.1371\/journal.pone.0107772","volume":"9","author":"M Sudo","year":"2014","unstructured":"Sudo, M. et al. Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition. PLoS One. 9: e107772 (2014).","journal-title":"PLoS One."},{"key":"BFsrep10809_CR8","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"RAC Hughes","year":"2007","unstructured":"Hughes, RAC. et al. Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review. Brain. 130: 2245\u22122257 (2007).","journal-title":"Brain"},{"key":"BFsrep10809_CR9","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","volume":"21","author":"U von Pawel-Rammingen","year":"2002","unstructured":"von Pawel-Rammingen, U., Johansson, BP. & Bj\u00f6rck, L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 21: 1607\u22121615 (2002).","journal-title":"EMBO J."},{"key":"BFsrep10809_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000332940","volume":"4","author":"U von Pawel-Rammingen","year":"2012","unstructured":"von Pawel-Rammingen, U. Streptococcal IdeS and its impact on immune response and inflammation. J Innate Immun. 4: 132\u2212140 (2012).","journal-title":"J Innate Immun"},{"key":"BFsrep10809_CR11","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/brain\/awg235","volume":"126","author":"BC Jacobs","year":"2003","unstructured":"Jacobs, BC. et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 126: 2220\u22122234 (2003).","journal-title":"Brain"},{"key":"BFsrep10809_CR12","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awm316","volume":"131","author":"SK Halstead","year":"2008","unstructured":"Halstead, SK. et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 131: 1197\u22121208 (2008).","journal-title":"Brain"},{"key":"BFsrep10809_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jneuroim.2008.09.016","volume":"205","author":"V Phongsisay","year":"2008","unstructured":"Phongsisay, V. et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barr\u00e9 syndrome. J Neuroimmunol. 205: 101\u2212104 (2008).","journal-title":"J Neuroimmunol"},{"key":"BFsrep10809_CR14","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.22930","volume":"56","author":"KS Nandakumar","year":"2007","unstructured":"Nandakumar, KS., Johansson, BP., Bj\u00f6rck, L. & Holmdahl, R. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum. 56: 3253\u22123260 (2007).","journal-title":"Arthritis Rheum"},{"key":"BFsrep10809_CR15","doi-asserted-by":"publisher","first-page":"e1692","DOI":"10.1371\/journal.pone.0001692","volume":"3","author":"BP Johansson","year":"2008","unstructured":"Johansson, BP., Shannon, O. & Bj\u00f6rck, L. IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS One. 3: e1692 (2008).","journal-title":"PLoS One."},{"key":"BFsrep10809_CR16","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/ndt\/gfq115","volume":"25","author":"R Yang","year":"2010","unstructured":"Yang, R. et al. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol Dial Transplant. 25: 2479\u22122486 (2010).","journal-title":"Nephrol Dial Transplant"},{"key":"BFsrep10809_CR17","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1124\/mol.113.086470","volume":"83","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip, L., Asavapanumas, N. & Verkman, AS. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol. 83: 1268\u20131275 (2013).","journal-title":"Mol Pharmacol."},{"key":"BFsrep10809_CR18","first-page":"Cd000213","volume":"7","author":"JM Wardlaw","year":"2014","unstructured":"Wardlaw, JM., Murray, V., Berge, E. & del Zoppo, GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 7: Cd000213 (2014).","journal-title":"Cochrane Database Syst Rev."},{"key":"BFsrep10809_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.it.2008.04.009","volume":"29","author":"HU Lutz","year":"2008","unstructured":"Lutz, HU. & Fumia, S. Therapeutic cleavage of IgG is dangerous in humans. Molecular immunology. Trends Immunol. 29: 353\u2013354 (2008).","journal-title":"Trends Immunol."},{"key":"BFsrep10809_CR20","unstructured":"Hansa Medical AB, Safety Study on IdeS in Healthy Volunteers. In: ClinicalTrials.gov [online]. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01802697. (Accessed: 27January 2015.)"},{"key":"BFsrep10809_CR21","unstructured":"Hansa Medical AB, Phase II Study to Evaluate Safety and Efficacy of Intravenous Immunoglobulin G Degrading Enzyme of Streptococcus Pyogenes (IdeS) in Chronic Kidney Disease. In: ClinicalTrials.gov [online]. Available at: http:\/\/www.clinicaltrials.gov\/show\/NCT02224820. (Accessed: 10 April 2015.)"},{"key":"BFsrep10809_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","volume":"10","author":"BR Wakerley","year":"2014","unstructured":"Wakerley, BR., Uncini, A. & Yuki, N. New clinical criteria for Guillain-Barr\u00e9 and Miller Fisher syndromes. Nat Rev Neurol. 10: 537\u2212544 (2014).","journal-title":"Nat Rev Neurol."},{"key":"BFsrep10809_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1468-1331.2006.01466.x","volume":"13","author":"IN van Schaik","year":"2006","unstructured":"van Schaik, IN. et al. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol. 13: 802\u2212808 (2006).","journal-title":"Eur J Neurol"},{"key":"BFsrep10809_CR24","unstructured":"Ministry of Health, Singapore, NMEC Ethical Guidelines on Research Involving Human Subjects. Available at: https:\/\/www.moh.gov.sg\/content\/dam\/moh_web\/Publications\/Guidelines\/National%20Medical%20Ethics%20Committee%20Guidelines\/1997\/human_bmr.pdf. (Accessed: 27 January 2015.)"},{"key":"BFsrep10809_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/jnnp.2010.205856","volume":"82","author":"N Yuki","year":"2011","unstructured":"Yuki, N., Watanabe, H., Nakajima, T. & Sp\u00e4th. PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 82: 87\u221291 (2011).","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep10809","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:22:55Z","timestamp":1672960975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep10809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,9,1]]}},"alternative-id":["BFsrep10809"],"URL":"https:\/\/doi.org\/10.1038\/srep10809","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,21]]},"assertion":[{"value":"4 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Takahashi has no relevant disclosures. Prof. Yuki serves as an editorial board member of Expert Review of Neurotherapeutics, The Journal of the Neurological Sciences, The Journal of Peripheral Nervous System, Neurosurgery & Psychiatry.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10809"}}